INAB
IN8bio Inc

1,859
Loading...
Loading...
News
all
press releases
12 titres de soins de sant en mouvement lors de la session apr s-cl ture le 09/04/2024
Gagnants Le titre IN8bio (NASDAQ:INAB) a augment mardi de 31,19% 1,43 dollars lors de la session after-market. L'action ImmuCell (NASDAQ:ICCC) a grimp de 11,11% 5,80 dollars. L'action aTyr...
Benzinga·1y ago
News Placeholder
More News
News Placeholder
We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St·1y ago
News Placeholder
IN8bio (NASDAQ:INAB) Receives New Coverage from Analysts at Laidlaw
Laidlaw initiated coverage on shares of IN8bio (NASDAQ:INAB Free Report) in a report published on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $7.50 price...
Zolmax·1y ago
News Placeholder
IN8bio initiated with bullish view at Laidlaw, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission...
Globe Newswire·1y ago
News Placeholder
IN8bio (NASDAQ:INAB) vs. Compugen (NASDAQ:CGEN) Head-To-Head Contrast
Compugen (NASDAQ:CGEN Get Free Report) and IN8bio (NASDAQ:INAB Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two...
Zolmax·2y ago
News Placeholder
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented.The platform has demonstrated...
Globe Newswire·2y ago
News Placeholder
IN8bio to Present at Upcoming Investor Conferences
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present...
Business Wire·2y ago
News Placeholder
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapyNEW YORK, Feb. 14, 2024...
Globe Newswire·2y ago
News Placeholder
IN8bio (NASDAQ:INAB) Stock Price Down 7.7%
Shares of IN8bio, Inc. (NASDAQ:INAB Get Free Report) fell 7.7% during trading on Thursday . The company traded as low as $1.19 and last traded at $1.20. 618,406 shares changed hands during...
Zolmax·2y ago

Latest INAB News

View

Advertisement. Remove ads.

Advertisement. Remove ads.